tirzepatide for weight loss cost Newer Weight-Loss Drugs Not Cost-effective at Current Prices Tirzepatide Cost for Medical Weight

It can improve endothelial function and act as a calcium channel blocker and vasodilator

nevertheless, more long-term investigations are necessary

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for two primary indications: type 2 diabetes mellitus (marketed as Mounjaro) and chronic weight management (marketed as Zepbound)

Both are FDA-approved for adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure or high cholesterol

These observations were corroborated by single-cell calcium imaging studies in slices of arcuate nuclei, demonstrating that GLP-1MK-801 inhibits the NMDA-induced intracellular calcium surge relative to GLP-1 alone (Extended Data Fig